UBS analyst Dan Leonard has adjusted his price target for Danaher (DHR, Financial), reducing it from $275 to $240. Despite this adjustment, he maintains a Buy rating on the company's shares. This move reflects shifts within Danaher's business landscape, particularly noting that while there has been a recovery in the company's bioprocess operations, there has been a noticeable decline in the life sciences sector. Leonard's analysis suggests a mixed performance across different business divisions, influencing this revised outlook.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 22 analysts, the average target price for Danaher Corp (DHR, Financial) is $247.75 with a high estimate of $310.00 and a low estimate of $215.00. The average target implies an upside of 28.99% from the current price of $192.07. More detailed estimate data can be found on the Danaher Corp (DHR) Forecast page.
Based on the consensus recommendation from 28 brokerage firms, Danaher Corp's (DHR, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Danaher Corp (DHR, Financial) in one year is $242.21, suggesting a upside of 26.11% from the current price of $192.07. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Danaher Corp (DHR) Summary page.
